Comparing Metformin vs Ozempic for Weight Loss and Diabetes

Metformin is a popular medication for treating type 2 diabetes and has been around since the 1950s. It’s part of a drug class called biguanides and is often the first choice due to its effectiveness, safety, and low cost. Over the years, diabetes treatments have advanced, with more options available to help control blood sugar and sometimes aid in weight loss.

Ozempic, with the active ingredient semaglutide, is a newer option approved in 2017. It’s a GLP-1 receptor agonist, taken as a once-weekly injection, and it not only helps manage blood sugar but also promotes weight loss.

While Metformin has been reliable for many years, Ozempic brings a new approach with its weekly injection and extra help with weight loss. In this article, we’ll look at how both medications work, compare their benefits and side effects, and see how they fit into today’s diabetes care and weight loss strategies.

What’s the Difference Between Metformin and Ozempic?

Efficacy of Ozempic vs Metformin

Most clinical trials focus on how Ozempic works alongside metformin rather than head-to-head comparisons. This is likely because the two drugs play different roles in the treatment pathway.

Metformin is typically the first-line treatment when lifestyle changes fail to sufficiently lower blood sugar levels. Ozempic, on the other hand, is generally introduced when metformin or other oral medications are no longer effective in managing blood glucose.

Although direct comparisons are limited, separate studies show that both medications are effective for the following conditions:

Ozempic vs Metformin for Type 2 Diabetes

In the SUSTAIN 5 trial, participants taking semaglutide (Ozempic) as an add-on to basal insulin saw up to 1.8% HbA1c reduction vs. only 0.1% with a placebo after 30 weeks. Similarly, metformin monotherapy has been shown to decrease mean HbA1c by 1.3%, compared with a 0.4% increase in the placebo group after 29 weeks.

Additionally, a peer-reviewed 2023 meta-analysis confirmed that HbA1C reductions were significantly higher when metformin was used in combination with other medications, including GLP-1 RAs, compared to metformin alone.

Both drugs are proven to effectively lower blood glucose levels, with Ozempic potentially offering a greater reduction in HbA1c levels.

Health Warning!

While metformin-based combination therapy can lead to enhanced glycemic control, it’s important to consider the potential risks and adverse reactions that may arise from using multiple medications. Always consult a doctor before starting any new treatment.

Ozempic vs Metformin for Weight Loss

Metformin has been the subject of multiple studies regarding its impact on weight loss. In an earlier study from the Diabetes Prevention Program (DPP), participants experienced a nearly 6-pound weight loss after one year. However, a 2020 study suggests that while metformin does reduce BMI by about one unit, it may not lead to enough weight loss to be classified as a weight loss drug.

In contrast, Ozempic has shown more pronounced weight loss effects, often observed as a side effect during treatment. The table below highlights the observed weight loss on Ozempic across the SUSTAIN trials.

Ozempic vs Metformin for PCOS and Insulin Resistance

Polycystic ovary syndrome (PCOS) is a common hormonal disorder that impacts 4% to 12% of women in their reproductive years. Moreover, around 50% to 70% of women with PCOS have insulin resistance (IR), which is a major factor in the development of the condition.

Metformin is often used to improve insulin sensitivity and reduce IR. It’s also a first-choice treatment for helping women with PCOS who struggle with infertility. In a 10-year study, researchers found that long-term metformin use in overweight or obese women with PCOS led to weight loss, improved insulin sensitivity, better androgen levels, and a low rate of progression to diabetes.

Ozempic has also been studied for weight loss in PCOS patients. This is important because weight loss has been shown to improve insulin sensitivity, which may also help alleviate symptoms of PCOS.

In one recent study, obese women with PCOS who didn’t lose weight through lifestyle changes were treated with semaglutide (0.5 mg weekly). After three months, they lost an average of 16.76 lbs and saw their BMI drop by 3.1. Remarkably, almost 80% of the women achieved at least a 5% weight reduction.

Did You Know?

There is a bidirectional relationship between insulin resistance and weight gain, where each one contributes to the development of the other. This cycle can make it harder to manage both weight and insulin sensitivity.

Read our article on insulin resistance and weight gain to explore this connection further!

Ozempic vs Metformin Side Effects

Both medications are generally considered safe and well-tolerated, though gastrointestinal side effects like diarrhea, nausea, and vomiting are relatively common. Up to 30% of patients taking metformin experience these issues, while around 20% of patients in clinical trials reported similar side effects with Ozempic.

More serious but rare side effects are associated with both drugs. Metformin carries a risk of lactic acidosis while Ozempic has been linked to potential thyroid tumors (in animal studies), pancreatitis, and gallbladder issues. Additionally, some individuals may experience complications like low blood sugar (when used with other diabetes medications), and kidney problems.

Metformin vs Ozempic’s Mechanism of Action

Metformin works in multiple ways to control blood sugar and enhance the body’s response to insulin. Here’s how metformin works:

• • Reducing Glucose Production in the Liver: The liver produces glucose through a process called gluconeogenesis. In type 2 diabetes, this process is often too active, leading to high blood sugar. Metformin blocks this process, reducing the amount of glucose the liver releases into the blood, helping to lower fasting blood sugar.

• • Improving Insulin Sensitivity: Metformin helps the body use insulin more effectively. It increases glucose uptake in muscles, allowing them to use more glucose for energy, which reduces blood sugar levels, especially after eating.

Ozempic works differently by targeting GLP-1 receptors, which are involved in controlling blood sugar and appetite. Here’s how Ozempic delivers its benefits:

• • Increasing Insulin Release: Ozempic triggers insulin release from the pancreas when blood sugar levels are high. It only works when blood sugar is elevated, lowering the risk of hypoglycemia.

• • Lowering Glucagon Levels: By reducing glucagon, a hormone that tells the liver to produce glucose, Ozempic helps keep blood sugar levels in check.

• • Slowing Digestion: Ozempic slows the emptying of food from the stomach into the intestines, leading to a more gradual rise in blood sugar after meals.

• • Suppressing Appetite and Promoting Weight Loss: Ozempic also affects GLP-1 receptors in the brain, reducing hunger and leading to weight loss, which is beneficial for managing type 2 diabetes.

Fun Fact!

Many patients have reported that Ozempic reduces “food noise.” This means fewer constant thoughts and cravings about food, making it easier to manage appetite and avoid overeating.

Approved Indications of Metformin Versus Ozempic

Ozempic is approved for improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. In comparison, Metformin is approved for both adults and pediatrics aged 10 years and older for the same purpose.

Ozempic also has an added indication for reducing the risk of major cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes who have known cardiovascular disease. Metformin, on the other hand, does not have FDA approval for cardiovascular risk reduction.

While both medications have shown benefits for weight loss, PCOS, and improving insulin sensitivity, they are not FDA-approved for these conditions. Doctors may prescribe them off-label for such uses. However, Ozempic’s active ingredient, semaglutide, is available in another form called Wegovy, which is FDA-approved specifically for weight management.

Dosing Schedule of Metformin vs Ozempic

The dosing schedules of Ozempic and Metformin differ significantly in terms of frequency, form, and administration.

Metformin comes in the form of an oral tablet and is taken either once or twice daily, depending on the formulation. Specifically:

• • Immediate-release form: Typically taken twice daily with meals. The starting dose is 500 mg once or twice daily or 850 mg once daily. This can be increased weekly in increments of 500 or 850 mg to reach a typical maintenance dose of 850–1000 mg twice daily.

• • Extended-release form: Taken once daily, usually with the evening meal. The initial dose is 500 or 1000 mg daily, titrated in weekly 500 mg increments, with a maximum dose of 2000 mg per day.

Meanwhile, the dosing schedule of Ozempic involves a subcutaneous injection administered once weekly. The starting dose is 0.25 mg per week for the first 4 weeks. After this period, the dose is increased to 0.5 mg weekly. If additional glycemic control is needed, the dose can be further escalated to 1 mg after 4 weeks and eventually to 2 mg weekly if necessary. The maximum recommended dose is 2 mg weekly.

Unlike Metformin, Ozempic is injected under the skin and is administered just once a week, which may be more convenient for patients who prefer less frequent dosing.

Ozempic vs Metformin Cost and Generic Availability

Metformin, with its long history of use and availability as a generic, remains an affordable option for many patients. Depending on the dosage and form (immediate-release or extended-release), the average price of Metformin without insurance is between $4 and $15 per month for generic versions.

If purchased through discount programs or as part of a bulk supply, costs can be as low as $0.37 per pill. Brand-name versions, such as Glucophage and Glumetza, are more expensive, retailing up to $100 per tablet.

Ozempic comes with a much steeper price tag compared to generic Metformin. As a relatively new drug, Ozempic is still under patent protection, which prevents the availability of lower-cost generic versions. Ozempic’s list price is $968.52 per package, though it typically sells for $900 to $1,500 per month.

Get your Ozempic and Metformin from PharmaGiant today!

Many Americans choose more affordable options, like Canadian pharmacy partners that ship directly to the US. Here at PharmaGiant, customers can save up to 90% on prescription medications, including Ozempic. Larger orders come with extra discounts, and new customers get 10% off with code PGSAVE10. Medications arrive in 3-5 days, with special care for temperature-sensitive items.

Which is Better, Ozempic or Metformin?

When comparing Metformin vs Ozempic, the choice largely depends on individual health needs, goals, and financial considerations. Metformin is a safe, affordable first-line treatment, especially suitable for those newly diagnosed with type 2 diabetes or seeking a low-cost option.

Ozempic, though more expensive, provides superior blood sugar control and significant weight loss, making it more suitable for individuals managing both diabetes and obesity. It also offers cardiovascular protection for those at risk of heart disease.

To ensure the best treatment plan, individuals should consult their healthcare provider, taking into account their medical history and overall health goals.

Frequently Asked Questions

Sources

Rodbard, H. W., Lingvay, I., Reed, J., De La Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P., Wijayasinghe, N., & Norwood, P. (2018). Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. The Journal of Clinical Endocrinology & Metabolism, 103(6), 2291–2301. https://doi.org/10.1210/jc.2018-00070

Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021). Should metformin remain the first-line therapy for treatment of type 2 diabetes? Therapeutic Advances in Endocrinology and Metabolism, 12, 204201882098022. https://doi.org/10.1177/2042018820980225

Khan, R. A., Patel, N., Folajimi, A., Bai, B. R., Patel, V., Komminni, P. K., Palleti, S. K., & Hirani, S. (2023). Comparison of the efficacy and safety of Metformin-Based Combination therapy versus Metformin alone in children and Adolescents with Type 2 Diabetes Mellitus: A Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.35014

Sorli, C., Harashima, S., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017a). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251–260. https://doi.org/10.1016/s2213-8587(17)30013-x

Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The Lancet Diabetes & Endocrinology, 5(5), 341–354. https://doi.org/10.1016/s2213-8587(17)30092-x

Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2017). Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, randomized clinical trial. Diabetes Care, 41(2), 258–266. https://doi.org/10.2337/dc17-0417

Aroda, V. R., Bain, S. C., Cariou, B., Pileti?, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology, 5(5), 355–366. https://doi.org/10.1016/s2213-8587(17)30085-2

Bray, G. A., Edelstein, S. L., Crandall, J. P., Aroda, V. R., Franks, P. W., Fujimoto, W., Horton, E., Jeffries, S., Montez, M. G., Mudaliar, S., Pi-Sunyer, F. X., White, N. H., & Knowler, W. C. (2012). Long-Term safety, tolerability, and weight loss associated with Metformin in the Diabetes Prevention Program Outcomes study. Diabetes Care, 35(4), 731–737. https://doi.org/10.2337/dc11-1299

Pu, R., Shi, D., Gan, T., Ren, X., Ba, Y., Huo, Y., Bai, Y., Zheng, T., & Cheng, N. (2020). Effects of metformin in obesity treatment in different populations: a meta-analysis. Therapeutic Advances in Endocrinology and Metabolism, 11, 204201882092600. https://doi.org/10.1177/2042018820926000

Attia, G. M., Almouteri, M. M., & Alnakhli, F. T. (2023). Role of metformin in polycystic ovary syndrome (PCOS): related infertility. Cureus. https://doi.org/10.7759/cureus.44493

Jensterle, M., Kravos, N. A., Ferjan, S., Goricar, K., Dolzan, V., & Janez, A. (2020b). Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocrine Connections, 9(1), 44–54. https://doi.org/10.1530/ec-19-0449

Fonseca, V. A., Capehorn, M. S., Garg, S. K., Gimeno, E. J., Hansen, O. H., Holst, A. G., Nayak, G., & Seufert, J. (2019). Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. The Journal of Clinical Endocrinology & Metabolism, 104(9), 4078–4086. https://doi.org/10.1210/jc.2018-02685

Carmina, E., & Longo, R. A. (2023). Semaglutide Treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. Journal of Clinical Medicine, 12(18), 5921. https://doi.org/10.3390/jcm12185921

Kommu, S., & Whitfield, P. (2024). Semaglutide. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK603723/

Corcoran, C., & Jacobs, T. F. (2023). Metformin. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK518983/

FDA. (2017, Dec). Highlights Of Prescribing Information of Ozempic. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf